S-1: Kraig Biocraft Laboratories Files for Potential $10 Million Stock Resale by YA II PN, Ltd.

Kraig Biocraft Laboratories has filed a registration statement for the potential resale of up to 207,787,193 shares of its common stock by YA II PN, Ltd., under a standby equity purchase agreement.

Summary

• Kraig Biocraft Laboratories has filed a registration statement for the potential resale of up to 207,787,193 shares of its common stock by YA II PN, Ltd.
• The shares are related to a standby equity purchase agreement (SEPA) where Yorkville (YA II PN, Ltd.) committed to purchase up to $10 million of Kraig Biocraft's common stock.
• As consideration for Yorkville's commitment, Kraig Biocraft issued 1,081,471 commitment shares.
• Kraig Biocraft will not receive any proceeds from the resale of shares by Yorkville, but may receive up to $10 million from sales of its common stock to Yorkville under the SEPA.
• The company's common stock is currently quoted on the OTCQB under the symbol KBLB, with the last reported sales price on February 6, 2025, at $0.0975 per share.
• The company intends to use any proceeds received from sales to the Selling Stockholder for working capital and general corporate purposes.

Sentiment

Score: 4

Explanation: The document is neutral in tone, presenting factual information about a stock resale agreement. The potential for dilution and price decline tempers any positive aspects of securing funding.

Positives

• The SEPA provides Kraig Biocraft with a potential source of funding up to $10 million.
• The company retains control over the timing and amount of stock sales to Yorkville under the SEPA.
• The company has the right to terminate the SEPA under certain conditions.

Negatives

• The resale of shares by Yorkville could result in a decline in the public trading price of Kraig Biocraft's common stock.
• Existing stockholders' economic and voting interests will be diluted as a result of any stock issuance under the SEPA.
• The company's management has broad discretion over the use of net proceeds from the sale of shares to Yorkville.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital and achieving sustainable revenues.
• The company has a limited operating history and may not be able to generate significant revenues or become profitable.
• The company faces competition from larger companies with greater financial resources.
• The company's business, operations, and plans could be adversely affected by health epidemics, including COVID-19.
• The company may be unable to maintain an effective system of internal controls.
• The company's management team will have broad discretion over the use of the net proceeds from our sale of shares of Common Stock to the Selling Stockholder, if any, and you may not agree with how we use the proceeds, and the proceeds may not be invested successfully.

Future Outlook

The company expects to use the net proceeds that it receives from sales of its Common Stock to the Selling Stockholder, if any, under the SEPA for working capital and general corporate purposes.

Industry Context

The announcement reflects a common financing strategy for smaller public companies, particularly in speculative sectors, to secure funding through equity-linked agreements. These agreements can provide flexibility but also carry risks of dilution and price volatility.

Comparison to Industry Standards

• The use of a standby equity purchase agreement is a financing mechanism employed by companies like PolarityTE and Diffusion Pharmaceuticals, which, like Kraig Biocraft, are in the development stage and require flexible access to capital.
• The potential dilution from the resale of shares is a risk factor similar to that faced by other companies utilizing shelf registrations, such as those seen in filings by companies in the biotechnology and renewable energy sectors.
• The reliance on a single investor for a significant portion of funding is a concentration risk comparable to situations where smaller pharmaceutical companies depend heavily on milestone payments from larger partners.

Stakeholder Impact

• Shareholders may experience dilution of their ownership and potential decline in stock price.
• The company may secure additional funding for its operations.
• The market may react to the potential for increased stock supply.

Next Steps

• The SEC needs to declare the registration statement effective.
• Kraig Biocraft may then, at its discretion, direct Yorkville to purchase shares of common stock under the SEPA.
• Yorkville may then offer, sell, or distribute all or a portion of its shares of common stock publicly or through private transactions.

Key Dates

Keywords

common stock, SEPA, Yorkville, Kraig Biocraft Laboratories, resale, shares, offering, stock